Campath transplantation

Alemtuzumab (campath-lH) is a humanized monoclonal antibody specific for the CDw52 antigen, present on cell membranes of lymphocytes and monocytes. It has been used for treatment of patients with rheumatoid arthritis and vasculitis, is being investigated for the treatment of chronic lymphocytic leukemia, and has been used to deplete circulating lymphocytes in patients with multiple sclerosis (1). In 2001, alemtuzumab was approved in Europe for the treatment of chronic B cell lymphocytic leukemia that had been treated previously with alkylating agents and was refractory to fludarabine (2). It has also been used for induction of immunosuppression/tolerance in liver transplant recipients (3,4) and kidney/pancreas transplant recipients (5). 

Varadi G, Or R, Rund D, Orbach H, Slavin S, Nagler A. Severe migratory polyarthritis following in vivo CAMPATH-IG. Bone Marrow Transplant 1995 16(6) 843-5. 

Alemtuzumab (Campath) Anti-CD52 Ab - B-cell chronic lymphocytic leukemia - Preconditioning regimen for bone marrow and renal transplantation -HUS -Acute renal failure - Acute humoral rejection 98,99,101... 

Hill P,Gagllardlnl E, RuggenentI P, RemuzzI G Severe early acute humoral rejection resulting In allograft loss In a renal transplant recipient with Campath-1 H Induction therapy, Nephrol Dial Transplant 2005,20 1741-1744... 

I. F. Khouri, M. Albitar, R. M. Saliba, C. Ippoliti, Y. C. Ma, M. J. Keating, and R. E. Camplin, Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant 33 833-837 (2004). 

Caine R, Moffatt SD, Friend PJ, et al. Campath-IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplant 1999 68 1613. 

Knechtle SJ, Pirsch JD, Becher BN, et al. Campath-IH induction plus rapamycin monotherapy in renal transplantation (abstract). Am J Transplant 2002 2 S459. 

Reams BD, Davis RD, Curl J, Palmer SM. Treatment of refractory acute rejection in a lung transplant recipient with campath IH. Transplanation 2002 74 903. 

Rebello, P.R.U.B., Hale, G., Friend, P.J., Cobbold, S.P., and Waldmann, H. (1999) Anti globulin responses to rat and humanized CAMPATH 1 monoclonal antibody used to treat transplant rejection. Transplantation, 68, 1417 1419. 

Buyck HC, Prentice HG, Griffiths PD, Emery VC. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant 2010 45 1212-9. 

T cell depletion of bone marrow piM) harvests using Campath-IM in [laediatric haemopoietic transplantation 3S3... 

Anecdotal responses have been cited with cyclosporin A (206), monoclonal antibodies targeted against T cells (207,208) humanized anti-CD4 antibodies (18), alemtuzumab (CAMPATH-IH), a monoclonal antibody directed against CD52 (81,209), 15-deoxyspergualin (210,211), and etoposide (180,212), and autologous hematopoietic stem cell transplants (213), but data are limited to a few cases in uncontrolled trials. 

---